+91 9891296838 / 9811747774
ORFADIN is a 4-hydroxyphenylpyruvate dioxygenase inhibitor indicated for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of ORFADIN (nitisinone) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the medicine and its cost price in India.
The order for ORFADIN (nitisinone) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Nitisinone is used to treat hereditary tyrosinemia type 1 (HT-1) in patients from all ages, in combination with dietary restriction of tyrosine and phenylalanine.
ORFADIN® (nitisinone) capsules, for oral use. ORFADIN® (nitisinone) oral suspension. Initial U.S. Approval: 2002
Generic Name: nitisinone
Capsules: 2 mg, 5 mg, 10 mg, 20 mg. (3)
Oral suspension: 4 mg/mL
60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand ORFADIN (nitisinone) on prescription and Import License in Patient's Name only.
For overseas patients, ORFADIN (nitisinone) can be made available in Send your enquiry to find ORFADIN (nitisinone) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
FDA Approves New Generic for Rare HT-1 Disorder
FDA approves ORFADIN® (nitisinone) Oral Suspension For More Details